Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of a Structured Intervention to Optimize Both the Use of Mirabegron, a β3 Receptor Agonist, and Facilitate Its Discontinuation: a Quasi-experimental Study

NCT03536494 is registered in ClinicalTrials.gov with Catalan Institute of Health as lead sponsor.

NCT NCT03536494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03536494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of a Structured Intervention to Optimize Both the Use of Mirabegron, a β3 Receptor Agonist, and Facilitate Its Discontinuation: a Quasi-experimental Study
Lead sponsor
Catalan Institute of Health
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2017
Completion date
December 31, 2017
Enrollment
1,932 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder syndrome